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Abstract
Calcium signaling in the brain is fundamental to the learning and memory process and there is evidence to suggest
that its dysfunction is involved in the pathological pathways underlying Alzheimer’s disease (AD). Recently, the
calcium hypothesis of AD has received support with the identification of the non-selective Ca2+-permeable channel
CALHM1. A genetic polymorphism (p. P86L) in CALHM1 reduces plasma membrane Ca2+ permeability and is
associated with an earlier age-at-onset of AD. To investigate the role of CALHM1 variants in early-onset AD (EOAD),
we sequenced all CALHM1 coding regions in three independent series comprising 284 EOAD patients and 326
controls. Two missense mutations in patients (p.G330D and p.R154H) and one (p.A213T) in a control individual were
identified. Calcium imaging analyses revealed that while the mutation found in a control (p.A213T) behaved as wild-
type CALHM1 (CALHM1-WT), a complete abolishment of the Ca2+ influx was associated with the mutations found in
EOAD patients (p.G330D and p.R154H). Notably, the previously reported p. P86L mutation was associated with an
intermediate Ca2+ influx between the CALHM1-WT and the p.G330D and p.R154H mutations. Since neither
expression of wild-type nor mutant CALHM1 affected amyloid ß-peptide (Aß) production or Aß-mediated cellular
toxicity, we conclude that rare genetic variants in CALHM1 lead to Ca2+ dysregulation and may contribute to the risk
of EOAD through a mechanism independent from the classical Aß cascade.
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Introduction
Key neuronal processes including neurotransmission,
synaptic plasticity, learning and memory are regulated by
intracellular calcium (Ca2+) levels, and alterations in Ca2+
dynamics have dramatic consequences in signaling cascades,
cytoskeleton modifications, synaptic function, and neuronal
survival [1,2]. Since the first formal hypothesis was posed
twenty years ago [3], many studies have supported the
essential role of Ca2+ dysregulation in central pathological
processes related to Alzheimer’s disease (AD) [4,5].
Disturbances in Ca2+ signaling have been evidenced during the
initial phases of AD, even before the accumulation of the
amyloid ß-peptide (Aß), a pathological hallmark of AD [6-10]. A
large body of work also indicates that mutations in genes
unequivocally related to AD, such as the presenilins, the
amyloid precursor protein or the apolipoprotein-E lead to
alterations in Ca2+ signaling, which in turn leads to apoptosis,
impairment of synaptic plasticity and neurodegeneration
[11-16].
Recently, a novel Ca2+ conducting channel, named CALHM1
(for calcium homeostasis modulator 1), has been proposed as
a key modulator of intracellular Ca2+ homeostasis [17-19].
Characterization of this protein disclosed a multipass, highly
conserved transmembrane glycoprotein preferentially
expressed in the brain. Electrophysiological data have
demonstrated that CALHM1 is the pore subunit of a plasma
membrane non-selective channel that regulates cortical
neuronal excitability and Ca2+ homeostasis in response to
extracellular Ca2+ levels and voltage [20]. Genetic
epidemiological studies have suggested that a proline-to-
leucine polymorphism (rs2986017) at residue 86 (p. P86L) in
CALHM1 could modify the age-at-onset of AD [17,21-23], albeit
this was not observed in all association studies [24,25].
Prompted by the large body of literature relating Ca2+
dysregulation to AD, and the possible influence of CALHM1
gene variation on AD age-at-onset, we investigated if rare
variants in CALHM1 found in early-onset forms of AD (EOAD)
could influence Ca2+ homeostasis.
Materials and Methods
Patients and controls
Three independent EOAD series from Spain, Sweden and
Finland were included in this study. All the patients were
previously screened for mutations in Mendelian AD genes,
including PSEN1, PSEN2 and APP, and found to be negative.
The Spanish series consisted of 98 unrelated EOAD patients
with a mean age-at-onset of 54.1±5.6 years (range 33-64
years). All patients were selected from a previous multi-center
study [26]. One hundred forty-three cognitively healthy Spanish
control individuals with an average age at blood extraction of
69.6±13.2 years were recruited from Hospital Sant Pau
(Barcelona) and Hospital La Paz (Madrid). An additional 384
neurologically healthy individuals (81±7.6 years) from Hospital
Marqués de Valdecillas, were included as a confirmatory
group. The Finnish series consisted of 116 EOAD cases
(59.7±4.8 years of age at onset, range 43-65 years) obtained
from the Kuopio University Hospital, Finland. The Swedish
series comprised 70 EOAD patients with a mean age-at-onset
of 54.7±5.1 years (range 41-60 years), and 166 controls
(75.3±6.1 years) recruited from the Memory Disorder Unit at
the Uppsala University Hospital. For all patients, the diagnosis
was established according to the National Institute on
Neurological Disorders and Stroke, and the Alzheimer's
Disease and Related Disorders Association (NINDS-ADRDA)
guidelines [27].
Ethics Statement
Approval was obtained from the ethics committee or
institutional review board of each institution responsible for the
ascertainment and collection of samples (Hospital Sant, Pau,
Hospital Marqués de Valdecillas, Hospital La Paz, Kuopio
University Hospital, and Uppsala University Hospital). Written
informed consent was obtained from all participants or
representatives.
Genetic analysis
CALHM1 exons and intronic flanking regions were amplified
by PCR using the primers 5'-CTCTGAGCTCTGTTGGTCCC-3'
and 5'-AGGCCCCATTTTGAGAGGTAG-3' for exon 1, and
primers 5'-CTGGCATAGAGAGTGCTTTGG-3' and 5'-
AGTACTGCCCAGCACTGAAAC-3' for exon 2, and Roche
FastStart PCR Master Mix polymerase (Roche Diagnostics
Corp., Indianapolis, USA). Cycle sequencing was performed on
purified PCR products with Applied Biosystems BigDye
terminator v3.1 sequencing chemistry and run on an ABI 3100
(Applied Biosystems, California, USA) genetic analyzer as per
the manufacturer’s instructions. The sequences were analyzed
with Sequencher software, version 4.2 (Gene Codes Corp.,
Michigan, USA). The p.G330D genotyping was performed by
restriction fragment length polymorphism approach using the
BtsCI restriction enzyme to digest a PCR-amplified product of
672 base-pairs (bp). DNA from the patient with the p.G330D
mutation was used as positive control in all experiments. All
fragments were resolved by electrophoresis on 2% agarose
gels stained with ethidium bromide. Presence of the mutation
resulted in three bands of 271, 250, and 151 bp whereas its
absence resulted in two bands of 271 and 401 bp (primer
sequences provided upon request). Protein sequences were
aligned with ClustalW2 (http://www.ebi.ac.uk/Tools/clustalw2/
index.html). Bioinformatic tools PMut [28], Panther version 7
[29] and PolyPhen-2 [30] were used to predict the impact of
rare amino acid exchanges on protein structure and function.
CALHM1 subcloning and mutagenesis
Human CALHM1 cDNA was obtained from Origene
(Maryland, USA). CALHM1-P86L, CALHM1-R154H, CALHM1-
A213T, and CALHM1-G330D non-synonymous changes were
introduced with the QuickChange II site-directed mutagenesis
kit (Stratagene), and confirmed by direct sequencing.
To detect transfected CALHM1 using confocal microscopy,
plasmids containing CALHM1-WT and CALHM1-P86L tagged
at the C-terminal with a myc tag as previously described [17]
was kindly provided by Philippe Marambaud. Plasmids
containing CALHM1-R154H, CALHM1-A213T, and CALHM1-
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G330D were introduced with the QuickChange II site-directed
mutagenesis kit (Stratagene), and confirmed by direct
sequencing.
Cell culture and transfections
HEK 293 cells, HEK cells stably expressing the Swedish
APP mutation (HEK-APPsw, generous gift from Dennis Selkoe)
[31], and CHO cells expressing wild-type APP and wild-type
PSEN1 (Ps70) [32], were used in this study. Cells were
cultured in DMEM with 10% fetal bovine serum (FBS) at 37°C
with 5% CO2 in a tissue culture incubator. All transfections
were performed using Fugene (Invitrogen, California, USA),
polyethylenimine ExGen500 (Fermentas MBI) or XtremeGene
(Roche) according to manufacturer’s instructions. Conditioned
medium was collected 6-24 h after transfection. To compare
the expression of the transfected wild-type and mutant
CALHM1, Ps70 cells were transfected with CALHM1 tagged
with myc. Twenty four hours after transfection, the cells were
fixed with 4% paraformaledhide and immunostained for
transfected CALHM1 using mouse anti-myc (9E10, 1:100, EMD
Millipore Corporation, USA) and goat anti-mouse Alexa555
antibodies (1:200 Life Technologies Corporation). Confocal
images were taken with an SP5 confocal microscope (Leica
Microsystems GmbH, Wetzlar, Germany) using a 555nm
wavelength (63x objective; 4x zoom). Confocal images were
taken in multiple z planes (1micron apart) in order to capture
the whole cell. The z plane at the midpoint of the cell was used
for the confocal images presented here. Confocal images
(Figure S1) showed that transfected mutant and wild-type
CALHM1 were equally and highly expressed in Ps70 cells and
demonstrated a similar pattern of cellular localization.
Ca2+add-back assay
Transfected cells were grown in normal DMEM (containing
1.8 mM Ca2+) plus 10% FBS. Twenty-four hours after
transfection cells were washed three times with CaCl2/MgCl2-
free Hanks’ balanced salt solution (HBSS), supplemented with
1.7 mM MgCl2 and then incubated for 30 min in this medium.
Ca2+-free HBSS was removed and cells were maintained for 6
hours in HBSS with 1% FBS. Cells were then washed with
phosphate-buffered saline (PBS) and conditioned medium was
collected for Aβ measurements.
Calcium imaging
Cytosolic Ca2+ signals were obtained from cells loaded with
4.5 μM fura-2 AM as previously described [33]. Cytosolic [Ca2+]
alterations are presented as the ratio of emitted fluorescence
(510 nm) after excitation at 340 nm and 380 nm, relative to the
ratio measured prior to cell stimulation (ratio 340/380). Imaging
experiments were conducted in an isotonic bath solution (10
mM Tris-HEPES, pH 7.3, 140 mM NaCl, 2.5 mM KCl, 1.2 mM
CaCl2, 0.5 mM MgCl2, 5 mM glucose). Osmolarity was adjusted
to 310 mOsm using mannitol.
Aβ measurements
Human Aβ was measured by ELISA in the conditioned
medium 6 hours after Ca2+ add-back. The levels of Aß1-40 and
Aß1-42 were measured using commercial enzyme-linked
immunosorbent assay kits (IBL, Gumna, Japan) as previously
described [34].
Aβ1-42 oligomer preparation
Synthetic Aβ1-42 (EZBiolab) oligomers were obtained by
dissolving 300 μg freeze-dried aliquots in 20 μL DMSO.
Peptide stock aliquots were diluted in 0.1 M Tris-HCl at pH 7.4
to a final concentration of 88.6 μM Aß. Solutions were stirred
continuously at 37°C and 300 rpm for 3 h and kept at -80 °C
before being used.
Cell viability assay
HEK cells over-expressing CALMH1-WT, CALHM1-P86L
and CALHM1-G330D were seeded in 96-well plates at a
density of 3x104 cells/100μL/well. Then 2 µM Aβ1-42 oligomers
were added for 24h. Cell viability was measured by 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) reduction as previously described [35]. Briefly, 11 μL of
MTT stock solution (5 mg/mL) were added and after 2 h the
reaction was stopped with 120 μL of DMSO. MTT reduction
was determined in a plate reader spectrophotometer at 540
and 650 nm. The values for untreated cells were taken as
100%.
Statistical analysis
Data are expressed as mean±SEM for every set of
experiments. Statistical analysis was assessed with one-way
analysis of variance (ANOVA) using Sigma-Plot and GraphPad
Prism 5 software.
Results
Identification of CALHM1 mutations
Mutation screening of the CALHM1 gene in EOAD patients
disclosed a heterozygous G to A transition (c.G989A), which
results in the replacement of a glycine to aspartic acid at codon
330 (p.G330D) in a Spanish patient. In addition, a p.R154H
missense mutation (c.G461A) was found in a Swedish patient
(Figure 1A). Exhaustive CALHM1 genetic screening in the
control series disclosed just one rare amino acid change
(p.A213T), which was found in a healthy individual from the
Swedish series (Figure 1A). To rule out that the p.G330D was
a common variant within the Spanish population, 384 healthy
additional controls belonging to the same geographic ancestry
were subjected to RFLP analysis. The genetic variant was not
found in any of these control samples.
The patient carrying the p.G330D mutation was a female in
whom the first clinical symptoms appeared at the age of 56.
Her father had been diagnosed with AD at the age of 65 and
died at the age of 68 years. Also, a 78 year old first-cousin has
been suffering from dementia since the age of 60. Neither DNA
nor further detailed clinical information was available from
these two affected family members. The patient with the
p.R154H mutation was a female in whom symptoms started at
the age of 55 and who died at the age of 76. Both her mother
and maternal uncle had dementia at the age of 60 years. The
CALHM1 Rare Variants and Alzheimer's Disease
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analysis of the only available DNA sample from this family,
belonging to a 63 year-old healthy daughter, did not disclose
this genetic variant.
The potential pathogenicity of these three missense
mutations was assessed in silico by three different softwares
(Table 1). Both PMut and Panther predicted profound
perturbations of protein function in mutations carried by EOAD
patients (p.R154H and p.G330D), whereas no pathological
effects were anticipated for the p.A213T variant carried by a
control individual. Predictions from the PolyPhen-2 software
indicated a damaging effect for the p.R154H variant but also for
the p.A213T, whereas no deleterious effects were predicted for
the p.G330D variant. All substitutions are conserved across
vertebrate species (Figure 1B).
CALHM1 missense mutations alter Ca2+ homeostasis
To address whether these variants affect Ca2+ entry into the
cytosol, we conducted Ca2+ influx measurements in HEK-293
cells expressing wild-type or mutant CALHM1 and loaded with
the cytosolic Ca2+ dye Fura-2 (Figure 2A). Mean increases in
the peak Ca2+ signal measured 1 min after the addition of Ca2+
to the extracellular solution are shown in Figure 2B. Following a
transient depletion of extracellular Ca2+, and consistent with
previous reports, we observed that re-addition of extracellular
Ca2+ to cells transfected with CALHM1-WT generated a strong
and sustained increase in cytosolic Ca2+ concentration. This
intracellular Ca2+ elevation was significantly higher than in cells
expressing the CALHM1-P86L polymorphism, also in
accordance with a previous report [17]. As shown in Figure 2B,
the two mutations identified in EOAD patients, CALHM1-
G330D and CALHM1-R154H, produced further attenuated Ca2+
increases that were no different from control GFP-transfected
cells. On the other hand, the CALHM1-A213T mutation found
in a healthy subject generated a Ca2+ influx similar to CALHM1-
WT.
Figure 1.  Novel non-synonymous mutations identified in
the CALHM1 gene.  A. Electropherograms showing wild-type
(upper) and mutated (bottom) sequences with the CALHM1
missense mutations highlighted. B. Partial protein sequence
alignment of CALHM1 from various species. The sequence of
human CALHM1 (NM_001001412.3) was aligned with its
orthologs in Pan troglodytes (XM_521596.2), Mus musculus
(NM_001081271.1) and Caenorhabditis elegans
(NM_063002.2).
doi: 10.1371/journal.pone.0074203.g001
CALHM1 mutations do not alter Aβ levels or Aβ-
mediated cell toxicity
We next determined whether these novel CALHM1 variants
influence Aβ levels. We transfected HEK-APPsw cells with
wild-type and mutant CALHM1 constructs and measured Aβ
levels by ELISA in the medium 6 and 24 hours after Ca2+-add-
back. We did not find any clear effect of these variants on Aβ40
(Figure 3A) or Aβ42 levels (Figure 3B), and the Aβ42/Aβ40
ratios were similar in all cases (Figure 3C). Similar results were
obtained in CHO cells co-expressing APP-WT and CALHM1
proteins (data not shown).
We also tested whether the expression of different CALHM1
proteins modified cell viability in the absence or the presence of
2 μM Aβ oligomers. Cell viability was measured by MTT
reduction in HEK-293 cells transiently transfected with
CALHM1-WT, CALHM1-P86L and CALHM1-G330D (Figure 4).
Cell viability was equally reduced in the presence of Aβ for both
wild-type and mutant CALHM1-expressing cells, therefore
discarding a role of disease associated mutations of CALHM1
in Aβ-induced cell toxicity. Similar results were obtained when
cells over-expressing the different CALHM1 proteins were
challenged with hydrogen peroxide (data not shown).
Table 1. Predictions of the functional impact of novel
CALHM1 variants.
 Mutation PMut* Panther† PolyPhen-2‡
Spanish
series     
EOAD (n=98) p.G330D Pathological(0.64)
Pathological
(-3.21) Benign (0.069)
Controls
(n=160) -    
Swedish
series     
EOAD (n=70) p.R154H Pathological(0.58)
Pathological
(-4.15)
Probably
damaging (0.993)
Controls
(n=166) p.A213T Neutral (0.14)
Not pathological
(-2.23)
Probably
damaging (0.995)
Finnish series     
EOAD
(n=116) -    
*Prediction of pathological consequences of the amino acid exchange predicted by
PMut software. A pathogenicity index ranging from 0 to 1 is provided. Mutations
associated with an index above 0.5 are considered pathological.
†Panther classification system of each of the amino acid substitutions. The
numbers in parenthesis refer to the substitution position-specific evolutionary
conservation score (based on an alignment of evolutionarily related proteins), from
0 (neutral) to about - 10 (most likely to be deleterious). - 3 is the previously
identified cut-off point for functional significance.
‡PolyPhen-2 refers to the pathogenicity prediction on Polymorphism Phenotyping,
version 2. Prediction scores are presented in parenthesis (zero indicates benign
and 1 damaging).
doi: 10.1371/journal.pone.0074203.t001
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Figure 2.  Effect of CALHM1 mutations on Ca2+ influx.  A. HEK-293 cells transfected with GFP, CALHM1-WT, CALHM1-P86L,
CALHM1-R154H, CALHM1-A213T and CALHM1-G330D were loaded with Fura-2 and tested for Ca2+ influx into the cytoplasm
following the removal of Ca2+ from the extracellular media. Time course of Ca2+ signals normalized to the value before the addition
of Ca2+ and expressed as the mean±S.E.M. are shown. B. Mean peak Ca2+ signals for the different conditions are shown. Number of
cells analysed are given for each condition. * P<0.05 vs GFP; ** P<0.01 vs GFP, one-way ANOVA and Bonferroni post hoc.
doi: 10.1371/journal.pone.0074203.g002
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Discussion
Our systematic mutation screening of CALHM1 in patients
with EOAD has revealed two novel missense variants
(p.R154H and p.G330D) in two patients and a non-
synonymous variant (p.A213T) in a control individual. In silico
analyses by two independent methods (PMut and Panther)
predicted that the p.R154H and p.G330D missense variants,
but not p.A213T, would have important effects on protein
function. However, a third predictor (PolyPhen-2) yielded
inconclusive results. We therefore performed a comprehensive
analysis of these three rare genetic variants to assess their
Figure 3.  Effect of CALHM1 mutations on the production
of.  Aβ1-40 and Aβ1-42.
HEK- APPsw cells transfected with GFP and the different
CALHM1 constructs were tested for the production of (A) Aβ1-40
and (B) Aβ1-42. The ratio Aβ 1-42/Aβ1-40 is shown in C. Data are
mean±SEM values of four independent experiments.
doi: 10.1371/journal.pone.0074203.g003
influence on the functional properties of the CALHM1 ion
channel. Our results are intriguing because they strongly
indicate that the p.R154H and p.G330D genetic variants found
in EOAD patients with a positive family history of AD have
important consequences in CALHM1 function (namely,
extracellular Ca2+ influx), whereas the p.A213T variant carried
by an asymptomatic elderly control did not. Furthermore, we
found that the p. P86L polymorphism, previously shown to
modify the age-at-onset of AD, had an intermediate effect
between CALHM1-WT and the novel pathogenic variants. In
contrast to a previous report [17], we could not find any
changes in extracellular Aß levels or Aß-mediated toxicity in
cells expressing either the p. P86L or any of the variants
described here, despite their more severe effect on CALHM1
channel activity. Our data strongly argue against a direct
impact of CALHM1 on Aβ production or Aß-mediated cell
toxicity. Instead, we postulate that the implication of CALHM1
in the pathophysiology of AD is most likely related to CALHM1-
induced Ca2+ dyshomeostasis. In fact, disruption of Ca2+
signaling is an early event in the pathogeneis of AD, prior to
cognitive decline and neuronal death, and expression of genes
associated with Ca2+signaling have been shown to be
significantly altered in concomitance with the progression of
Alzheimer’s pathology [10]. Since intracellular Ca2+ levels are
tightly controlled in cells, these sustained disturbances in Ca2+
homeostasis lead to a wide range of harmful processes such
as synaptic transmission alterations and plasticity impairment
[5]. Therefore, although the exact mechanism underlying
CALHM1-induced changes in the pathogenesis of AD cannot
be elucidated from our data, we hypothesize that alterations in
CALHM1 properties can have significant consequences in early
Figure 4.  Effect of CALHM1 on Aβ 1-42- induced cell
toxicity.  HEK-293 cells over-expressing CALHM1-WT,
CALHM1-G330D and CALHM1-P86L were treated with 2 μM
Aβ1-42 oligomers for 24h. Cell viability was measured by MTT
reduction. Data are the mean ± SEM of three independent
experiments performed in triplicate. * P<0.05 vs untreated cells
by student t test.
doi: 10.1371/journal.pone.0074203.g004
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AD pathways, including neuronal excitability [20], and synaptic
function [36-38].
Taken together, our results suggest that rare genetic variants
in CALHM1 disturb Ca2+ homeostasis and may contribute to the
development of EOAD. More generally, our data strongly
support the calcium hypothesis as a relevant event in the
pathogenesis of AD. We propose that the mechanism by which
CALHM1 dysregulation may contribute to AD is unlikely related
to Aβ production and cytotoxicity, and that a potential role of
CALHM1 in neuronal excitability merits further investigation.
Supporting Information
Figure S1.  Wild-type and mutant CALHM1 exhibit similar
expression and localization patterns in Ps70 cells.
CALHM1 was visualized using antibodies against the myc tag.
(TIF)
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